Eye problems after Botox: crow’s feet, dry eye, what to do
After a botulinum toxin injection at the corner of the eyes, crow’s feet may look too frozen, the eye may become dry, the eyelid may swell, and the smile may sometimes change. These effects are known and temporary. This page presents them, the warning signs and a page for each one.
Crow’s feet, the small fan-shaped lines at the corner of the eyes, are one of the areas treated with botulinum toxin. The injected muscle, the orbicularis oculi, surrounds the eye and helps close the eyelids: this explains most of the possible problems in this region. This page is part of our guide for when something goes wrong after an injection, organised area by area.
What problems can affect the eye area?
Problems around the eyes
Two situations are specific to this area: crow’s feet that are too frozen, which make the smile less expressive around the eyes, and dry eye. Two other pages, attached to other areas, may also follow an injection at the corner of the eye: the puffy eyelid and the asymmetric smile.
The labels describe these effects. After treatment of crow’s feet, one type A toxin classes eyelid swelling, dry eye and bruising at the injection site as common1. With another product, bruising at the injection site is common and eyelid swelling uncommon2. The first label also advises avoiding injections too close to the zygomaticus major muscle, which lifts the corner of the mouth, so as not to cause the lip to droop1: this is what can change the smile.
Each page details the cause, when it appears, how long it lasts and what can help.
Which signs mean you should see a doctor quickly?
Crow’s feet that are a little too smooth are bothersome but not dangerous. The eye, however, deserves particular attention. See a doctor promptly if your eye is painful or red, very dry, hard to close completely, or if your vision is blurred or double1,2,3. The short-acting botulinum toxin (serotype E) label points out that reduced blinking can lead to damage to the cornea, which requires vigorous treatment3. Any difficulty swallowing, speaking or breathing means calling emergency services (15 or 112 in France, or your local emergency number).
Write down the date of the injection and the day the problem appeared, and if possible contact the doctor who performed the injection.
Why is the corner of the eye injected?
When it contracts, especially when you smile, the orbicularis creases the skin at the corner of the eye. Relaxing it softens crow’s feet. For this area, only some type A toxins have an aesthetic indication in France1,2; the short-acting toxin is approved only for frown lines3, and as of 9 October 2026 in the European Union and Canada4,5. With these type A toxins, the effect on crow’s feet has been shown for up to 4 months1,2: this is also the usual maximum duration of an unwanted effect. To find out why and how crow’s feet are treated, see the page for this area in our atlas of treatment areas.
If it is mainly the eyelid that has changed, see the page on eyelids after an injection; if it is the smile, the page on the smile changed after an injection.
Frequently asked questions
Why can the eye become dry after an injection?
The muscle injected at the corner of the eye, the orbicularis, is also the one that closes the eyelids. If it is too relaxed, blinking may decrease: the short-acting toxin label points out that this reduced blinking, reported with other toxins, can lead to dry eye and even damage to the cornea3. With a type A toxin, dry eye is a common effect after treatment of crow’s feet1. A painful or red eye, or blurred vision, should prompt you to see a doctor promptly.
Sources
- 1.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 61592762) (opens in a new tab) — French public medicines database (BDPM)
- 2.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
- 3.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
- 4.European public assessment report (EPAR) of the serotype E botulinum toxin (opens in a new tab) — European Commission (Union Register of medicinal products)
- 5.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada